In sum, these findings provide evidence that FLT4 (VEGFR3/CD310) expression could serve as a valuable prognostic biomarker to stratify colorectal cancer patients and select those who will likely respond to fruquintinib-based treatments. Here, FLT4 is linked to colorectal cancer.